Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075192 · ClinicalTrials.gov registry record · Phase 1
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00075192 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 8 participants.
The verdict
NCT00075192, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a multi-center, open label, randomized study. Patients will be randomized to one of the following arms with an allocation ratio of 3:1, respectively: Arm A: CP-675,206 + neoadjuvant hormone therapy (NHT) OR Arm B: neoadjuvant hormone therapy. After randomization, patients will receive study treatment for three cycles (one cycle is defined as 28 days). After completion of three cycles, patients will undergo a prostatectomy and pathology assessments will be completed at a central laboratory, the Armed Forces Institute of Pathology (AFIP) in Washington, DC.
Interventions
- DRUG CP-675,206 and leuprolide acetate and bicalutamide
- DRUG leuprolide acetate and bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075192
The ClinicalTrials.gov registry entry for NCT00075192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CP-675,206 and leuprolide acetate and bicalutamide is the first listed.
NCT00075192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075192 about?
NCT00075192 is a clinical study titled "CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer". This is a multi-center, open label, randomized study. Patients will be randomized to one of the following arms with an allocation ratio of 3:1, respectively: Arm A: CP-675,206 + neoadjuvant hormone therapy (NHT) OR Arm B: neoadjuvant hormone therapy. After randomization, patients will receive study ...
What is the current status of trial NCT00075192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2004-03. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00075192?
The interventions under investigation include: CP-675,206 and leuprolide acetate and bicalutamide (DRUG), leuprolide acetate and bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00075192?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.